Geode Capital Management
CNSP icon

Geode Capital Management’s CNS Pharmaceuticals CNSP Stock Holding History

Geode Capital Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.7K Buy
+23,189
New +$96.1K ﹤0.01% 4287
2025
Q3 		– Sell
-1,489
Closed -$14.7K – 4492
2025
Q2 		$14.7K Buy
+1,489
New +$18.6K ﹤0.01% 4396
2025
Q1 		– Sell
-645
Closed -$46.6K – 4486
2024
Q4 		$46.6K Buy
645
+306
+90% +$21.8K ﹤0.01% 4254
2024
Q3 		$26.5K Buy
+339
New +$97.2K ﹤0.01% 4367
2024
Q2 		– Sell
-1
Closed -$10.2K – 4593
2024
Q1 		$10.2K Hold
1
– – ﹤0.01% 4551
2023
Q4 		$30.8K Hold
1
– – ﹤0.01% 4449
2023
Q3 		$27.4K Hold
1
– – ﹤0.01% 4561
2023
Q2 		$36K Buy
+1
New +$53.7K ﹤0.01% 4573
2022
Q4 		– Hold
0
– -$23K – 4904
2022
Q3 		– Hold
0
– – – 4894
2022
Q2 		– Hold
0
– – – 4846
2022
Q1 		– Hold
0
– – – 4830
2021
Q4 		– Hold
0
– – – 4792
2021
Q3 		– Hold
0
– – – 4525
2021
Q2 		– Hold
0
– – – 4349
2021
Q1 		– Hold
0
– – – 4210

Other funds holding CNSP

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management's CNSP Position: Q1 2026 in Review

Geode Capital Management opened a new position in CNS Pharmaceuticals (CNSP) in Q1 2026: 23,189 shares worth $55.7K. The stake represents ﹤0.01% of the portfolio and ranks #4287 among its holdings. This is a return to the name: Geode Capital Management previously reported a position in CNSP as recently as Q2 2025.

Geode Capital Management first reported a position in CNSP in Q2 2023 and has held it in 8 quarters since. 12 funds tracked by Wall St. Rank hold CNSP as of Q1 2026.

  • Geode Capital Management held 23,189 shares of CNS Pharmaceuticals worth $55.7K as of Q1 2026.
  • CNS Pharmaceuticals was a new Geode Capital Management position in Q1 2026.
  • CNS Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4287 holding.
  • Geode Capital Management first reported a position in CNS Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
  • 12 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.